Sherko K.
- Country
- Germany
- Department
- Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik für Senologie/ Brustzentrum
Research Overview
- Evaluation of Safety and Efficacy of Elacestrant in Combination Therapies for Patients with Metastatic Breast Cancer: A Phase 1b/2 Open-Label Umbrella Study
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
Data & Insights
Has run more than one trial at 405 of 761 partner sites.
Specializations
HER2-Positive Breast Cancer Research
Specializes in investigating novel therapeutic approaches for HER2-positive breast cancer, including early-stage and metastatic disease. Focuses on evaluating treatments combining trastuzumab and pertuzumab with emerging therapeutic agents.
- Chemotherapy-free treatment strategies
- Advanced therapeutic combinations
- Metabolic response assessment
Hormone Receptor-Positive Breast Cancer
Conducts research in hormone receptor-positive breast cancer treatment, particularly focusing on endocrine therapy combinations and novel targeted therapies. Investigates treatments for patients with ESR1 mutations and various therapeutic combinations.
- Advanced endocrine therapy approaches
- CDK4/6 inhibitor combinations
- Novel therapeutic agents
Triple Negative and High-Risk Breast Cancer
Expertise in treating triple negative breast cancer and high-risk breast cancer subtypes. Studies innovative approaches including immunotherapy combinations and targeted treatments for specific molecular subtypes.
- Neoadjuvant therapy approaches
- Immunotherapy combinations
- Molecular targeting strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.